In addition to its direct anti-tumor effects, concurrent anti-AR or anti-ERβ therapy is also expected to be beneficial for enhancing sensitivity to conventional non-surgical treatments for bladder cancer, particularly cisplatin therapy in men with AR-positive tumor or in women with ERβ-positive tumor, respectively. Here, ESR2 is linked to urinary bladder carcinoma.